1. Home
  2. PRLD vs JZXN Comparison

PRLD vs JZXN Comparison

Compare PRLD & JZXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • JZXN
  • Stock Information
  • Founded
  • PRLD 2016
  • JZXN 2019
  • Country
  • PRLD United States
  • JZXN China
  • Employees
  • PRLD N/A
  • JZXN N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • JZXN Retail-Auto Dealers and Gas Stations
  • Sector
  • PRLD Health Care
  • JZXN Consumer Discretionary
  • Exchange
  • PRLD Nasdaq
  • JZXN Nasdaq
  • Market Cap
  • PRLD 44.0M
  • JZXN 51.8M
  • IPO Year
  • PRLD 2020
  • JZXN 2021
  • Fundamental
  • Price
  • PRLD $1.01
  • JZXN $0.89
  • Analyst Decision
  • PRLD Strong Buy
  • JZXN
  • Analyst Count
  • PRLD 3
  • JZXN 0
  • Target Price
  • PRLD $4.00
  • JZXN N/A
  • AVG Volume (30 Days)
  • PRLD 133.9K
  • JZXN 168.2K
  • Earning Date
  • PRLD 08-14-2025
  • JZXN 09-08-2025
  • Dividend Yield
  • PRLD N/A
  • JZXN N/A
  • EPS Growth
  • PRLD N/A
  • JZXN N/A
  • EPS
  • PRLD N/A
  • JZXN N/A
  • Revenue
  • PRLD $7,000,000.00
  • JZXN $97,465.00
  • Revenue This Year
  • PRLD N/A
  • JZXN N/A
  • Revenue Next Year
  • PRLD N/A
  • JZXN N/A
  • P/E Ratio
  • PRLD N/A
  • JZXN N/A
  • Revenue Growth
  • PRLD N/A
  • JZXN N/A
  • 52 Week Low
  • PRLD $0.61
  • JZXN $0.83
  • 52 Week High
  • PRLD $5.95
  • JZXN $7.82
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 52.78
  • JZXN 39.76
  • Support Level
  • PRLD $0.75
  • JZXN $0.85
  • Resistance Level
  • PRLD $0.96
  • JZXN $1.10
  • Average True Range (ATR)
  • PRLD 0.08
  • JZXN 0.11
  • MACD
  • PRLD 0.01
  • JZXN 0.02
  • Stochastic Oscillator
  • PRLD 67.87
  • JZXN 15.42

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About JZXN Jiuzi Holdings Inc.

Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.

Share on Social Networks: